$ORY #Oryzon Genomics Oryzon Genomics - Third positive update from Phase II ALICE trial: Last Friday, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual 25th Congress of… https://t.co/OneWCzKGal #equity #stocks https://t.co/48OavPxTHi